Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study
- PMID: 34467980
- DOI: 10.1210/clinem/dgab644
Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study
Abstract
Context: Nonalcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction associated with fatty liver disease (MAFLD) recently.
Objective: We aimed to explore the risk of all-cause deaths in MAFLD participants and compare it with NAFLD in Chinese adults.
Methods: We enrolled 152 139 participants with abdominal ultrasonography in the Kailuan Cohort from 2006 to 2012. We categorized the participants into MAFLD and non-MAFLD, NAFLD and non-NAFLD, and 4 groups of Neither FLD, MAFLD only, NAFLD only, and MAFLD-NAFLD, respectively. We used Cox regression models to estimate the hazard ratios (HRs) and 95% CI of death.
Results: The prevalence of MAFLD and NAFLD was 31.5% and 27.3%, respectively. After a median follow-up of 12.7 years, MAFLD and NAFLD both were associated with increased mortality, especially in men younger than 40 years, with HR (95% CI) of 1.51 (1.19-1.93) and 1.37 (1.06-1.78), respectively. The MAFLD-only group had higher mortality than the NAFLD-only in males 60 years or older (adjusted HR = 1.43; 95% CI, 1.00-2.03) and lower risk in males aged 40 to 59 years (adjusted HR = 0.65; 95% CI, 0.48-0.90). MAFLD with overweight/obesity-only decreased, but those with diabetes and/or metabolic dysregulation increased the risk of death. MAFLD with positive hepatitis B surface antigen and/or excessive alcohol consumption further increased the risk of death, especially in men younger than 40 years (HR = 9.86; 95% CI, 2.44-39.98).
Conclusion: MAFLD was associated with increased all-cause mortality among the Chinese population, which was different according to the status of overweight/obesity, diabetes, other metabolic indicators, and second causes. MAFLD patients should be managed by metabolic indicators and second causes to fulfill precise treatment and management.
Keywords: alcohol consumption; metabolic dysfunction–associated fatty liver disease; metabolic dysregulation; nonalcoholic fatty liver disease; overweight; type 2 diabetes mellitus.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.Hepatol Int. 2022 Aug;16(4):835-845. doi: 10.1007/s12072-022-10362-3. Epub 2022 Jun 14. Hepatol Int. 2022. PMID: 35701716
-
Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.J Clin Endocrinol Metab. 2022 Jan 1;107(1):88-97. doi: 10.1210/clinem/dgab641. J Clin Endocrinol Metab. 2022. PMID: 34508601 Free PMC article.
-
Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.Epidemiol Health. 2024;46:e2024024. doi: 10.4178/epih.e2024024. Epub 2024 Jan 21. Epidemiol Health. 2024. PMID: 38317531 Free PMC article.
-
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Clin Mol Hepatol. 2021 Apr;27(2):257-269. doi: 10.3350/cmh.2021.0067. Epub 2021 Mar 22. Clin Mol Hepatol. 2021. PMID: 33751877 Free PMC article. Review.
-
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2. Eur J Clin Invest. 2021. PMID: 33583033 Review.
Cited by
-
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.Curr Issues Mol Biol. 2024 Jun 21;46(7):6300-6314. doi: 10.3390/cimb46070376. Curr Issues Mol Biol. 2024. PMID: 39057018 Free PMC article. Review.
-
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.Hepatol Int. 2024 May 28. doi: 10.1007/s12072-024-10671-9. Online ahead of print. Hepatol Int. 2024. PMID: 38806774
-
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0. BMC Med. 2024. PMID: 38448943 Free PMC article.
-
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare.BMC Public Health. 2024 Feb 20;24(1):532. doi: 10.1186/s12889-024-17851-0. BMC Public Health. 2024. PMID: 38378519 Free PMC article.
-
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk.Diagnostics (Basel). 2024 Jan 22;14(2):229. doi: 10.3390/diagnostics14020229. Diagnostics (Basel). 2024. PMID: 38275476 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical